F2RL1 and acute lymphoblastic leukemia: Blocking PAR2 in our experiments inhibited both the pathological [Ca2+]i elevations (figure 2e) and the asparaginase-induced necrosis (figure 5b), suggesting that PAR2 inhibitors in addition to, or in combination with, CRAC channel inhibitors could be a useful tool to supplement asparaginase ALL treatment in AAP cases.